Novel approaches to the pharmacological blockade of gastric acid secretion

Expert Opinion on Investigational Drugs

Volumn 14, Issue 4, 2005, Pages 411-421

  Parson, Michael E ^a   Keeling, David J ^b  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Gastrin receptor antagonists; GORD; H3 receptor agonists; H+ K+ ATPase; Potassium competitive acid blocker

Indexed keywords

1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 2 OXO 1 PIVALOYLMETHYL 5 (2 PYRIDYL) 1H 1,4 BENZODIAZEPIN 3 YL] 3 [3 (METHYLAMINO)PHENYL]UREA; 3 BUTYRYL 8 METHOXY 4 (2 METHYLANILINO)QUINOLINE; 8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; ALPHA METHYLHISTAMINE; AZD 0865; BENATOPRAZOLE; BETHANECHOL; BP 2 94; BY 841; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CS 526; DEOXYGLUCOSE; DIMAPRIT; ESOMEPRAZOLE; FAMOTIDINE; GASTRIN; GASTRIN ANTAGONIST; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; ILAPRAZOLE; IMETIT; IMIDAZOPYRIDINE DERIVATIVE; ITRIGLUMIDE; OMEPRAZOLE; PD 136450; PENTAGASTRIN; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM ION; PROTON PUMP INHIBITOR; PYRIDAZINE DERIVATIVE; R 105266; RANITIDINE; REVAPRAZAN; RP 73870; S 0509; SORAPRAZAN; SPIROGLUMIDE; THIOPERAMIDE; UNCLASSIFIED DRUG; Z 360;

CELL MEMBRANE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; GASTROESOPHAGEAL REFLUX; HUMAN; IC 50; LIVER TOXICITY; MEDICAL RESEARCH; MONOTHERAPY; NONHUMAN; REVIEW; STOMACH ACID SECRETION; STOMACH PARIETAL CELL;

ANIMALS; CLINICAL TRIALS; GASTRIC ACID; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE AGONISTS; HUMANS; PARIETAL CELLS, GASTRIC; POTASSIUM CHANNEL BLOCKERS; PROTON PUMPS; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, HISTAMINE H3;

EID: 19044386005     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.4.411     Document Type: Review

References (97)

1. VAN PINXTEREN B, NUMANS ME, LAU J, DE WIT NJ, HUNGIN AP, BONIS PA: Short-term treatment of gastroesophageal reflux disease. J. Gen. Intern. Med. (2003) 18:755-763.
2. CHIBA N, DE GARA CJ, WILKINSON JM, HUNT RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 112:1798-1810.
3. CRAWLEY JA, SCHMITT CM: How satisfied are chronic heartburn suffers with their prescription medications? Results of the patient unmet needs survey. J. Clin. Outcomes Management (2000) 7:29-34.
4. ANDERSSON T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. (1996) 31:9-28.
5. TONINI M, GIORGIO RD, PONTI FD: Novel therapeutic strategies in acid-related disorders. Expert Opin. Ther. Targets (2003) 13:639-649.
6. KIL BJ, KIM IW, SHIN CY et al.: Comparison of IY81149 with omeprazole in rat reflux oesophagitis. J. Auton. Pharmacol. (2000) 20:291-296.
7. DOMAGALA F, FICHEUX H: Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male caucasian volunteers. Gastroenterology (2003) 124:S1608 (Abstract).
8. GALMICHE JP, BRULEY DV, DUCROTTE P et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment. Pharmacol. Ther. (2004) 19:655-662.
9. TONINI M, DE GIORGIO R, DE PONTI F: Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs (2004) 64:347-361.
10. DAJANI EZ, KLAMUT MJ: Novel therapeutic approaches to gastric and duodenal ulcers: an update. Expert. Opin. Investig. Drugs (2000) 9:1537-1544.
11. VAKIL N: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (2004) 19:1-9.
12. 2 receptors. Nature (1972) 236:385-390.
13. 3 receptors in the regulation of gastric functions. J. Physiol. Pharmacol. (2001) 52:539-553.
14. PRINZ C, KAJIMURA M, SCOTT DR, MERCIER F, HELANDER HF, SACHS G: Histamine secretion from rat enterochromaffin like cells. Gastroenterology (1993) 105:449-461.
15. KIDD M, TANG LH, MIU K, LAWTON GP, SANDORA, MODLIN IM: Autoregulation of enterochromaffin-like cell histamine secretion via the histamine 3 receptor subtype. Yale J. Biol. Med. (1996) 69:9-19.
16. 3 receptors in isolated fundic mucosal cells. Am. J. Physiol. (1993) 265:G1039-G1044.
17. 3 receptors in isolated rabbit gastric glands. Am. J. Physiol. (1992) 262:G56-G61.
18. LINDSTROM E, BJORKQVIST M, BOKETOFT A et al.: Neurohormonal regulation of histamine and pancreastatin secretion from isolated rat stomach ECL cells. Regul. Pept. (1997) 71:73-86.
19. YOKOTANI K, MURAKAMI Y, OKADA S, WANG M, NAKAMURA K: Histamine H(3) receptor-mediated inhibition of endogenous acetylcholine release from the isolated, vascularly perfused rat stomach. Eur. J. Pharmacol. (2000) 392:23-29.
20. 3-receptor activation inhibits cholinergic stimulation of acid secretion in isolated rabbit fundic glands. J. Pharmacol. Exp. Ther. (1995) 275:1099-1103.
21. 3 receptors are not involved in the regulation of rat gastric secretion. Pharmacology (1992) 44:190-195.
22. 3 receptors, inhibits somatostatin and stimulates acid secretion in isolated mouse stomach. Gastroenterology (1997) 113:1545-1552.
23. 3 receptors are involved in the control of gastric acid secretion in the conscious cat. Naunyn Schmiedebergs. Arch. Pharmacol. (1991) 343:225-227.
24. 3 receptor in the control of gastric acid secretion in cats. Am. J. Physiol. (1991) 260:G631-G635.
25. 3 receptors. Br. J. Pharmacol. (1995) 115:1326-1330.
26. 3-receptor in vagal-, betanechol-, pentagastrin-induced gastric acid secretion in anaesthetized rats. Scand. J. Gastroenterol. (2002) 37:754-758.
27. 3 receptor-mediated inhibition of gastric acid secretion in conscious dogs. Naunyn Schmiedebergs. Arch. Pharmacol. (1993) 347:61-65.
28. 3 receptors in the dog. Scand. J. Gastroenterol. (1996) 31:631-638.
29. 3 receptors in the dog: an investigation into the site of action. Naunyn Schmiedebergs. Arch. Pharmacol. (1994) 350:218-223.
30. 3 receptor agonist prodrug. J. Pharmacol. Exp. Ther. (1997) 281:1085-1094.
31. 3-receptor agonist (R)-α-methylhistamine. Bioorg. Med. Chem. (2001) 9:191-198.
32. 3-receptor agonist. Curr. Med. Chem. (2001) 8:1329-1340.
33. 3-receptor agonist prodrug. Dig. Dis. Sci. (1999) 44:2380-2385.
34. FOZARD JR: BP-294 Ste Civile Bioproject. Curr. Opin. Investig. Drugs (2000) 1:86-89.
35. BLAIR AJ III, RICHARDSON CT, WALSH JH, FELDMAN M: Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology (1987) 92:944-949.
36. KIDD M, MODLIN IM, TANG LH: Gastrin and the enterochromaffin-like cell: an acid update. Dig. Surg. (1998) 15:209-217.
37. HOLST JJ, KNUHTSEN S, ORSKOV C, SKAK-NIELSEN T, POULSEN SS, NIELSEN OV: GRP-producing nerves control antral somatostatin and gastrin secretion in pigs. Am. J. Physiol. (1987) 253:G767-G774.
38. PRINZ C, SCOTT DR, HURWITZ D, HELANDER HF, SACHS G: Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am. J. Physiol. (1994) 267:G663-G675.
39. KOPIN AS, LEE YM, McBRIDE EW et al.: Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. USA (1992) 89:3605-3609.
40. SOLL AH, AMIRIAN DA, THOMAS LP, REEDY TJ, ELASHOFF JD: Gastrin receptors on isolated canine parietal cells. J. Clin. Invest. (1984) 73:1434-1447.
41. NOBLE F, WANK SA, CRAWLEY JN et al.: International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol. Rev. (1999) 51:745-781.
42. SANDVIK AK, WALDUM HL: CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. Am. J. Physiol. (1991) 260:G925-G928.
43. CHEY WY, SIVASOMBOON B, HENDRICKS J: Actions and interactions of gut hormones and histamine on gastric secretion of acid in the rat. Am. J. Physiol. (1973) 224:852-856.
44. KAMINSKI DL, RUWART MJ, JELLINEK M: Structure-function relationships of peptide fragments of gastrin and cholecystokinin. Am. J. Physiol. (1977) 233:E286-E292.
45. DELVALLE J, CHIBA T, PARK J, YAMADA T: Distinct receptors for cholecystokinin and gastrin on canine fundic D-cells. Am. J. Physiol. (1993) 264:G811-G815.
46. NISHIDA A, MIYATA K, TSUTSUMI R et al.: Pharmacological profile of (R)-1 -[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5 -phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3 -methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. (1994) 269:725-731.
47. NISHIDA A, TAKINAMI Y, YUKI H et al.: YM022 ([R]-1-(2,3-dihydro-1-[2′-methylphenacyl] -2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl) -3-[3-methylphenyl]urea), a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J. Pharmacol. Exp. Ther. (1994) 270:1256-1261.
48. PENDLEY CE, FITZPATRICK LR, CAPOLINO AJ et al.: RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J. Pharmacol. Exp. Ther. (1995) 273:1015-1022.
49. TAKEUCHI K, HIRATA T, YAMAMOTO H, KUNIKATA T, ISHIKAWA M, ISHIHARA Y: Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats. Aliment. Pharmacol. Ther. (1999) 13:87-96.
50. AMAGASE K, IKEDA K, OKABE S: Antisecretory and ulcer healing effects of S-0509, a novel CCK-B/gastrin receptor antagonist, in rats. Dig. Dis. Sci. (1999) 44:879-888.
51. STEEL K: Gastrin and gastrin receptor ligands - a review of recent patent literature. IDrugs (2002) 5:689-695.
52. BELTINGER J, HILDEBRAND P, DREWE J et al.: Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. Eur. J. Clin. Invest. (1999) 29:153-159.
53. BASTAKI SM, HASAN MY, CHANDRANATH SI, SCHMASSMANN A, GARNER A: PD-136450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity. Mol. Cell Biochem. (2003) 252:83-90.
54. MAKOVEC F, D'AMATO M: CCKB/gastrin receptor antagonists as potential drugs for peptic ulcer therapy. Drug Discov. Today (1997) 7:283-293.
55. MIURA N, YONETA T, UKAWA H et al.: Pharmacological Profiles of Z-360, a Novel CCK/Gastrin (CCK2) Receptor Antagonist with Excellent Oral Potency. Gastroenterology (2001) 120:A311 (Abstract).
56. MORITA H, MIURA N, HORI Y et al.: Effects of Z-360, a novel CCKB/gastrin (CCK2) receptor antagonist, on meal-induced acid secretion and experimental ulcer models in dogs and rats. Gastroenterology (2001) 120:A311 (Abstract).
57. MAKOVEC F, REVEL L, LETARI O, MENNUNI L, IMPICCIATORE M: Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. Eur. J. Pharmacol. (1999) 369:81-90.
58. BLACK JW, KALINDJIAN SB: Gastrin agonists and antagonists. Pharmacol. Toxicol. (2002) 91:275-281.
59. +-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochim. Biophys. Acta. (1973) 307:169-180.
60. METZ DC, FERRON GM, PAUL J et al.: Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J. Clin. Pharmacol. (2002) 42:512-519.
61. YAO X, FORTE JG: Cell biology of acid secretion by the parietal cell. Ann. Rev. Physiol. (2003) 65:103-131.
62. + channel KCNQ1 is essential for gastric acid secretion. Gastroenterology (2001) 120:1363-1371.
63. DEDEK K, WALDEGGER S: Colocalization of KCNQ1/KCNE channel subunits in the mouse gastrointestinal tract. Pflugers Arch. (2001) 442:896-902.
64. +)-pump. J. Physiol. (2002) 540:85-92.
65. + channels. Am. J. Physiol. Cell. Physiol. (2004) 286:C495-C506.
66. - channels in rabbit gastric mucosa. Am. J. Physiol. Cell. Physiol. (2001) 280:C1599-C1606.
67. SAKAI H, OKADA Y, MORII M, TAKEGUCHI N: Anion and cation channels in the basolateral membrane of rabbit parietal cells. Pflugers. Arch. (1989) 414:185-192.
68. + channels in the basolateral membrane of resting Necturus oxyntic cells. J. Membr. Biol. (1991) 123:209-221.
69. POST RL, HEGYVARY C, KUME S: Activation by adenosine triphosphate in the phosphorylation kinetics of sodium and potassium ion transport adenosine triphosphatase. J. Biol. Chem. (1972) 247:6530-6540.
70. ALBERS R: Biochemical aspects of active transport. Ann. Rev. Biochem. (1967) 36:727-756.
71. KUHLBRANDT W: Biology, structure and mechanism of P-type ATPases. Nat. Rev. Mol.. Cell. Biol. (2004) 5:282-295.
72. +)-ATPase. J. Biol. Chem. (1980) 255:5313-5319.
73. +-ATPase. J. Biol. Chem. (1996) 271:29764-29772.
74. +-competitive inhibitor site of gastric H/K-ATPase. Biochemistry (2001) 40:7480-7490.
75. +)-ATPase and site-directed mutagenesis of the putative cation binding site and catalytic center. J. Biol. Chem. (1996) 271:2740-2745.
76. + binding site of gastric H/K-ATPase. J. Biol. Chem. (2004) 279:16417-16424.
77. +)-ATPase. Biochem. Pharmacol. (1988) 37:2231-2236.
78. +-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2α)imidazole. J. Biol. Chem. (1987) 262:2077-2084.
79. + access to the ion binding domain. Biochemistry (2002) 41:12755-12762.
80. VAGIN O, MUNSON K, DENEVICH S, SACHS G: Inhibition kinetics of the gastric H/K-ATPase by K-competitive inhibitor SCH28080 as a tool for investigating the luminal ion pathway. Ann. NY. Acad. Sci. (2003) 986:111-115.
81. +)-ATPase. J. Biol. Chem. (1989) 264:5545-5551.
82. +)-competitive inhibitors in the gastric proton pump. J. Biol. Chem. (2004) 279:13968-13975.
83. BESANCON M, SIMON A, SACHS G, SHIN JM: Sites of reaction of the gastric H/K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. (1997) 272:22438-22446.
84. +/K(+)-ATPase inhibitors, omeprazole and E3810. J. Biol. Chem. (1993) 268:21553-21559.
85. ENE MD, KHAN-DANESHMEND T, ROBERTS CJ: A study of the inhibitory effects of SCH 28080 on gastric secretion in man. Br. J. Pharmacol. (1982) 76:389-391.
86. MARTINEK J, BLUM AL, STOLTE M et al.: Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment. Pharmacol. Ther. (1999) 13:27-34.
87. +/K(+)-transporting ATPase: a new class of anti-secretory agent. Trends Pharmacol. Sci. (1993) 14:323-325.
88. PARK S, AHN B, LEE B, KANG H, SONG K: Pharmacokinetics of YH1885. Gut (2003) 52(Suppl. VI):MON-G-008 (Abstract).
89. PARK S, LEE S, SONG K, LEE B, KANG H, KANG J: The pharmacological properties of a novel acid pump antagonist, YH1885. Gut (2003) 52(Suppl. VI):MON-G-009 (Abstract).
90. YU KS, BAE KS, SHON JH ET AL.: Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J. Clin. Pharmacol. (2004) 44:73-82.
91. +-ATPase selective, potassium-competitive acid blocker. Gastroenterology (2004) 126:A-333 (Abstract M1436).
92. HOLSTEIN B, HOLMBERG A, FLORENTZSON M, AURELL HOLMBERG A, ANDERSSON M, ANDERSSON K: AZD0865 - a new potassium-competitive acid blocker exhibits maximal gastric antisecretory effects from first dose. Gastroenterology (2004) 126:A-334 (Abstract M1437).
93. HOLSTEIN B, HOLMBERG A, FLORENTZSON M, AURELL HOLMBERG A, ANDERSSON M, ANDERSSON K: Pharmacokinetic and pharmacodynamic profiles of AZD0865, a novel, potassium-competitive acid blocker. Gastroenterology (2004) 126:A-334 (Abstract M1440).
94. ANDERSSON K, AURELL HOLMBERG A, BRIVING C, HOLSTEIN B: Preclinical profile of AZD0865, a novel, selective, potassium-competitive acid blocker. Gastroenterology (2004) 126:A-56 (Abstract 448).
95. HOLSTEIN, B, FLORENTZSON M, ANDERSSON M, ANDERSSON K: AZD-0865, a potassium-competitive acid blocker (P-CAB), has a long duration of effect in the rat. Am. J. Gastroenterol. (2004) 99(Suppl. 10):S8 (Abstract 22).
96. ITO K, KINOSHITA K, TOMIZAWA A et al.: The anti-secretory and anti-ulcer properties of R-105266, a novel acid pump antagonist. Gut (2001) 49(Suppl. III):(Abstract 3061).
97. +)-ATPase as both potential therapeutic agents and probes of pump function. Biochem. Soc. Trans. (1992) 20:566-572.